Medivir AB (publ) (MVRBF) & Its Rivals Financial Survey

Posted by Defense World Staff on Jun 24th, 2023

Medivir AB (publ) (OTCMKTS:MVRBF – Get Rating) is one of 440 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Medivir AB (publ) to similar businesses based on the strength of its earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Valuation and Earnings

This table compares Medivir AB (publ) and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Medivir AB (publ)	N/A	N/A	0.03
Medivir AB (publ) Competitors	$337.70 million	$40.71 million	-3.63

Medivir AB (publ)’s rivals have higher revenue and earnings than Medivir AB (publ). Medivir AB (publ) is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

23.2% of Medivir AB (publ) shares are held by institutional investors. Comparatively, 29.5% of shares of all “Biotechnology” companies are held by institutional investors. 23.3% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Medivir AB (publ) and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medivir AB (publ)	N/A	N/A	N/A
Medivir AB (publ) Competitors	-1,071.94%	-86.67%	-28.49%

Analyst Recommendations

This is a breakdown of recent ratings for Medivir AB (publ) and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medivir AB (publ)	0	0	1	0	3.00
Medivir AB (publ) Competitors	916	2400	7408	86	2.62

Medivir AB (publ) currently has a consensus price target of $50.00, suggesting a potential upside of 5,997.56%. As a group, “Biotechnology” companies have a potential upside of 130.26%. Given Medivir AB (publ)’s stronger consensus rating and higher probable upside, research analysts plainly believe Medivir AB (publ) is more favorable than its rivals.

Summary

Medivir AB (publ) beats its rivals on 7 of the 11 factors compared.

About Medivir AB (publ)

(Get Rating)

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.

Receive News & Ratings for Medivir AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medivir AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.